Showing results (61-70 of 130) with videos related to
Sort By:
Pageof 13
Journal of Cancer Research and Clinical Oncology|February 22, 2022
TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapyJulia Eckardt, Christopher Schroeder, Peter Martus, et al.Blood|October 31, 2008
Hematopoietic cell-derived interferon controls viral replication and virus-induced diseasePhilipp A Lang, Luisa Cervantes-Barragan, Admar Verschoor, et al.Frontiers in Immunology|February 17, 2025
Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysisKonstantinos Lallas, Eftychia Chatziioannou, Derya Durak, et al.European Journal of Cancer (Oxford, England : 1990)|February 18, 2024
Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IBTeresa Amaral, Lena Nanz, Rudolf Stadler, et al.American Journal of Clinical Dermatology|May 4, 2023
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based ImmunotherapyEftychia Chatziioannou, Ulrike Leiter, Ioannis Thomas, et al.Cancer Immunology, Immunotherapy : CII|October 28, 2020
Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitorsJohanna Winter, Max M Lenders, Maximilian Gassenmaier, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 16, 2019
Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor TreatmentStefan Diem, Mirjam Fässler, David Bomze, et al.Journal of Experimental & Clinical Cancer Research : CR|January 23, 2024
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapyFrancisco Meraz-Torres, Heike Niessner, Sarah Plöger, et al.Pigment Cell & Melanoma Research|March 21, 2024
Characterization of PRAME immunohistochemistry reveals lower expression in pediatric melanoma compared to adult melanomaStephan Forchhammer, Valentin Aebischer, Daniela Lenders, et al.Frontiers in Oncology|August 28, 2025
Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutationJulia Forschner, Julia Huynh, Christopher Schroeder, et al.Pageof 13